
Prior research has associated early adolescent use of hormonal contraceptives with the risk of depression in adulthood.

Prior research has associated early adolescent use of hormonal contraceptives with the risk of depression in adulthood.

IPX203 is a novel, oral formulation of carbidopa/levodopa extended-release capsules.

Five hours or less hours of sleep per night at 50 years of age was associated with a 25% higher risk of mortality over 25 years of follow-up.

Patients with Alzheimer disease administered gantenerumab did experience slower clinical decline, however, it was not deemed statistically significant.

A new study suggests that 30.5% of US adults lose out on 1 hour or more of sleep due to disturbances.

Cerebral adrenoleukodystrophy is a progressive neurodegenerative disease causes irreversible neurologic decline and can result in functional disabilities, such hearing loss and cortical blindness.

Daprodustat is suggested to improve anemia and quality-of-life in patients with chronic kidney disease.

Eisai plans to file for traditional approval in the United States by March 31, 2023.

Ozanimod is an oral, sphinogosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5.

Tacrine was originally brought to the market in 1993 as an acetylcholinesterase inhibitor to fight the symptoms of Alzheimer disease.

Deutetrabenazine is the only VMAT2 inhibitor approved by the FDA for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntington disease.

Although the treatment of motor symptoms is the primary focus of care for Parkinson disease, helping these patients with sleep disorders is vital because of the impact on quality of life.

The new data came from Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled (SHARP) study.

New research about the risks of dementia in patients with non-affective psychotic disorders could help shape new life course models for prevention.

New research suggests that psychedelics, and specifically ketamine, can increase neuroplasticity to help a patient with an eating disorder get “unstuck,” and help treat the disorder better than psychotherapy alone.

The history of targeting neuroinflammation is a good example of the challenges to finding a treatment for Alzheimer disease.

In a study of 2262 individuals, investigators also found that cocoa extract had no effect on cognition.

Changing one’s diet could change brain health and study results suggest the Mediterranean diet could positively support cognitive function.

Research suggests cannabis can improve quality of life for patients who suffer from pain and neurological disorders.

Cognitive harm appears reversible, results of analysis by Nemours Children’s Health Jacksonville and Stanford University shows.

Very short sleep among adolescents linked to a more than 70% increased risk of obesity/overweight in children, compared to those who get optimal 8 hours.

Industry partnerships will be essential to improving access to ketamine, according to expert Kevin Nicholson.

A new study suggests that work and private life mental stressors are disrupting sleep in older employees, potentially wreaking havoc on health.

Investigators used the FDA-approved concussions test i-STAT TBI Plasma and the company’s core laboratory Architect instrument.

The meta-analysis reviews 38 available studies on the effects of cognitive, physical, and social activities on brain function.